[{"orgOrder":0,"company":"DiogenX","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Endocrinology","graph2":"Preclinical","graph3":"DiogenX","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral","sponsorNew":"DiogenX \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"4","companyTruncated":"DiogenX \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AdipoPharma","sponsor":"Newton Biocapital","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2023","type":"Series A Financing","leadProduct":"PATAS","moa":"ALMS1","graph1":"Endocrinology","graph2":"Preclinical","graph3":"AdipoPharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AdipoPharma \/ Newton Biocapital","highestDevelopmentStatusID":"4","companyTruncated":"AdipoPharma \/ Newton Biocapital"},{"orgOrder":0,"company":"AdipoPharma","sponsor":"Newton Biocapital","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2024","type":"Funding","leadProduct":"PATAS","moa":"ALMS1","graph1":"Endocrinology","graph2":"Preclinical","graph3":"AdipoPharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"AdipoPharma \/ Newton Biocapital","highestDevelopmentStatusID":"4","companyTruncated":"AdipoPharma \/ Newton Biocapital"},{"orgOrder":0,"company":"Alize\u0301 Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"FRANCE","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Eneboparatide","moa":"Parathyroid hormone-1 receptor","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Alize\u0301 Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Alize\u0301 Pharma \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Alize\u0301 Pharma \/ Inapplicable"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : The funding will enable AdipoPharma to accelerate its clinical development of a first-in-class compound, PATAS, that directly targets insulin resistance, the root cause of Type 2 diabetes.

                          Product Name : PATAS

                          Product Type : Peptide

                          Upfront Cash : Undisclosed

                          November 11, 2024

                          Lead Product(s) : PATAS

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Preclinical

                          Sponsor : Newton Biocapital

                          Deal Size : Undisclosed

                          Deal Type : Funding

                          blank

                          02

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : The proceeds will advance company's lead drug, a potential first-in-class, disease-modifying recombinant protein designed to modulate the Wnt/β-catenin signalling pathway to regenerate pancreatic insulin-producing beta cells ,into clinical development i...

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          October 05, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Preclinical

                          Sponsor : Boehringer Ingelheim GmbH

                          Deal Size : $30.0 million

                          Deal Type : Series A Financing

                          blank

                          03

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : AdipoPharma uses a novel approach to treating Type 2 diabetes. AdipoPharma’s drug, PATAS, treats insulin resistance, the root cause of Type 2 diabetes. PATAS has been designed while working on fat cells known as adipocytes.

                          Product Name : PATAS

                          Product Type : Peptide

                          Upfront Cash : Undisclosed

                          January 23, 2023

                          Lead Product(s) : PATAS

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Preclinical

                          Sponsor : Newton Biocapital

                          Deal Size : Undisclosed

                          Deal Type : Series A Financing

                          blank

                          04

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Amolyt Pharma is developing AZP-3601, a parathyroid hormone analog specifically designed for the treatment of hypoparathyroidism, as well as AZP-3404, a peptide with a new and unique mechanism of action on fat and glucose metabolism.

                          Product Name : AZP-3601

                          Product Type : Peptide

                          Upfront Cash : Inapplicable

                          February 06, 2020

                          Lead Product(s) : Eneboparatide

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank